Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Mum On Consumer Business Plans As Analysts Say Spin-off

Executive Summary

Pfizer continues to review options for its consumer business, though analysts say a spin-off makes most sense. During its fourth-quarter earnings call, firm reported the division's US sales slumped 9% but 12% growth in international markets buoyed the worldwide results.

You may also be interested in...



Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

Biopharma Quarterly Dealmaking Statistics, Q1 2018

Biopharma financing started the year solidly with $16.6 billion in total deal value, a 14% increase over the previous quarter. Q1 2018 biopharma merger and acquisition deal value, led by Cigna's $67 billion buy of Express Scripts, topped even the previous all-time-high set in Q4 2107, while alliances totaled $30.7 billion and featured big oncology and neurology partnerships.

GSK Most Likely To Buy Pfizer's Consumer Business – Is It A Step In Wrong Direction?

UPDATE: SOON AFTER PUBLICATION OF THIS ARTICLE GSK ANNOUNCED IT HAD WITHDRAWN FROM THE BIDDING FOR PFIZER'S CONSUMER HEALTH BUSINESS. GSK looks likely to be the top bidder for Pfizer's consumer health business, with an offer announcement expected soon – but are more OTC products the answer to the UK major's longer-term sustainability and growth issues?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel